Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $192.5 million offering of common stock of Constellation Pharmaceuticals, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “CNST.”

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. The company is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associates Arisa Akashi and Alexander Kraik. Partner David R. Bauer and associates Christopher C. Woller and Jessica Brodman provided intellectual property advice. Partner William A. Curran and associate Alexander J. Hendin provided tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post